Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, MD, PhD
Published: Thursday, Jun 30, 2016



Maria-Victoria Mateos, consultant physician, hematology department, Hospital Universitario de Salamanca, MD, PhD, discusses the TOURMALINE-MM1 trial in multiple myeloma.
 
The phase III trial investigated the impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) compared to placebo plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
 
The IRd combination resulted in a significant improvement in progression free survival (PFS) compated to the control arm, says Mateos.
 
The benefit was sustained across different groups of patients regardless of prior lines of therapy.
 


Maria-Victoria Mateos, consultant physician, hematology department, Hospital Universitario de Salamanca, MD, PhD, discusses the TOURMALINE-MM1 trial in multiple myeloma.
 
The phase III trial investigated the impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) compared to placebo plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
 
The IRd combination resulted in a significant improvement in progression free survival (PFS) compated to the control arm, says Mateos.
 
The benefit was sustained across different groups of patients regardless of prior lines of therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x